Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma - Top-Institutions - MDSpire

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • By

  • Kevin Charles Miller

  • Patrick Connor Johnson

  • Jeremy S. Abramson

  • Jacob D. Soumerai

  • Andrew J. Yee

  • Andrew R. Branagan

  • Elizabeth K. O’Donnell

  • Anna Saucier

  • Caron A. Jacobson

  • Matthew J. Frigault

  • Noopur S. Raje

  • November 1, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunotherapy

  • #2

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunology

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Translational Research

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Clinical Research

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Hematology/Oncology
    • Cellular Therapy
    • Immunotherapy

Original Source(s)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • by Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje

  • November 1, 2022

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications